ONCOLife presents an exclusive interview with John Santini, CEO of Vergent Bioscience. In this session, we explore how ...

ONCOLife presents an exclusive interview with Dr. John Gribben, Professor at the Cancer Institute in London and Past ...

ONCOLife presents an exclusive interview with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative, as he shares his expert insights on the major barriers preventing eligible patients ...

We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...

ONCOLife presents an exclusive interview with Lorna Warwick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a ...

The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously treated non-squamous NSCLC with high c-Met overexpression. Backed by Phase 2 ...

ONCOLife presents an exclusive interview with Sarah Hein, CEO of March Biosciences. In this session, we explore clinical advancements in the field of CAR-T therapies, specifically on MB-105, a novel ...

AnX Robotica announced that its NaviCam ProScan, an AI-assisted tool for small bowel capsule endoscopy, has received FDA clearance.

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

Novartis announces its EUR 2.7 billion acquisition of MorphoSys AG, enhancing its oncology pipeline with promising treatments like pelabresib for myelofibrosis and tulmimetostat for solid tumors.

The first AI-powered companion diagnostic for non-small cell lung cancer has received FDA Breakthrough Device Designation. Developed by Roche, Ventana TROP2 RxDx Device combines IHC with a digital ...